Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the Peninsula Technology Assessment Group, University of Exeter:

  • Main C, Moxham T, Pitt M and Stein K, The clinical and cost-effectiveness of rituximab for the 1st line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche, January 2009

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Roche Products

II) Professional/specialist and patient/carer groups:

  • British Society for Haematology

  • Cancer Research UK

  • Chronic Lymphocytic Leukaemia Support Association

  • Leukaemia CARE

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • United Kingdom CLL Forum

III) Other consultees:

  • Department of Health

  • Hampshire Primary Care Trust

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Bayer

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Pharmacia

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on rituximab for the first-line treatment of chronic lymphocytic leukaemia by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Donald Milligan, Consultant Haematologist, NCRI, nominated by the Royal College of Physicians – clinical specialist

  • Professor Andrew Pettitt, Professor of Haematology, University of Liverpool, nominated by the Royal College of Pathologists – clinical specialist

  • Mrs Jane Barnard, nominated by the Chronic Lymphocytic Leukaemia Support Association – patient expert

  • Mrs Jacquelyn Williams Durkin, nominated by the Chronic Lymphocytic Leukaemia Support Association – patient expert

  • National Institute for Health and Care Excellence (NICE)